---
title: "The cancellation price per Frontage Holdings share is HK$2.37, a 107.2% premium to the 360-day… — 瑞銀 — DecisionGateway"
description: "statement by 瑞銀, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1e751-3025-769e-89ce-f5c5c2bcd583"
meta:
  "og:description": "statement by 瑞銀, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "The cancellation price per Frontage Holdings share is HK$2.37, a 107.2% premium to the 360-day… — 瑞銀 — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statement

# **The cancellation price per Frontage Holdings share is HK$2.37, a 107.2% premium to the 360-day average share price, equivalent to about 91.6 times Frontage's 2025 price-to-earnings ratio.**

A statement by [**瑞銀**](https://dgw.tmarket.io/actors/01a1d49e-d995-7396-8810-d1e55c335b54). Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *方達控股每股註銷價為2.37港元，較過去360日平均股價溢價107.2%，相當於方達控股2025年市盈率約91.6倍。*

stockintelligencenewsPublished 2026-11-11 [ Read source](https://t.me/stockintelligencenews/5715728)

[**瑞銀 dossier **](https://dgw.tmarket.io/actors/01a1d49e-d995-7396-8810-d1e55c335b54)

## **Discussion**

## **Related claims**

[**The cancellation price for each Frontage Holdings share is HK$2.37, a 107.2% premium to the average share price over the past 360 days, equivalent to about 91.6 times Frontage's 2025 price-to-earnings ratio.**瑞銀 · statement](https://dgw.tmarket.io/claims/01a1e74c-c283-7af5-b47d-a2e7fdfa6a10) [**Although divesting Frontage may affect some global synergies in the short term, the transaction can improve Tigermed's business portfolio and capital allocation while supporting further expansion of overseas clinical CRO business, supplementing working capital and raising shareholder returns.**瑞銀 · prediction](https://dgw.tmarket.io/claims/01a1e751-3094-73c5-92e4-9c2e1b97e4fa) [**After the privatization is completed, Tigermed plans to acquire Frontage's non-target business in mainland China at a preliminary valuation of about US$205.5 million; the target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; Frontage founder Li Song and related trusts may acquire the overseas non-target business at a preliminary valuation of about US$84.4 million.**瑞銀 · statement](https://dgw.tmarket.io/claims/01a1e74c-c295-7538-bc3f-a30a1cdabeb6) [**After the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses at a preliminary valuation of about US$205.5 million; target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.**瑞銀 · statement](https://dgw.tmarket.io/claims/01a1e751-3034-7cb6-8adc-d678204a44df) [**The liquidation price of the position is 73009 USD.**룩온체인 · statement](https://dgw.tmarket.io/claims/01a1e9ca-1122-7272-ba67-8be9691e680e) [**Tigermed announced it will participate in the privatization and business split of Frontage Holdings (01521) through its wholly-owned subsidiary Hong Kong Tigermed.**瑞銀 · statement](https://dgw.tmarket.io/claims/01a1e751-3011-7670-a475-41411a6a82cf)

## **More claims by 瑞銀**

[**Although divesting Frontage may affect some global synergies in the short term, the transaction can improve Tigermed's business portfolio and capital allocation while supporting further expansion of overseas clinical CRO business, supplementing working capital and raising shareholder returns.**prediction](https://dgw.tmarket.io/claims/01a1e751-3094-73c5-92e4-9c2e1b97e4fa) [**Tigermed plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A, 20% for daily operations, and the remaining about 20% possibly for dividends or share buybacks.**statement](https://dgw.tmarket.io/claims/01a1e751-3083-714b-9c7b-13200f21418b) [**If the transaction completes, Tigermed can divest non-core businesses including overseas laboratories, CMC and genomics to focus more on clinical CRO services.**prediction](https://dgw.tmarket.io/claims/01a1e751-306d-78f1-ac3c-2b57bdf9bbb3) [**Frontage's laboratory network in the US and Europe is an important platform linking Tigermed to global markets; it supports the strategy of dual IND filings in China and the US and helps Chinese innovative drugmakers expand overseas, so divesting Frontage may affect Tigermed's global footprint and cross-border drug R&D competitiveness to some extent.**statement](https://dgw.tmarket.io/claims/01a1e751-3054-7ca0-a7ed-2ee97b0ffbc4) [**After the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses at a preliminary valuation of about US$205.5 million; target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.**statement](https://dgw.tmarket.io/claims/01a1e751-3034-7cb6-8adc-d678204a44df)

[All claims by 瑞銀](https://dgw.tmarket.io/claims?claimant_id=01a1d49e-d995-7396-8810-d1e55c335b54)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts — every claim cited to its public source. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1e751-3025-769e-89ce-f5c5c2bcd583#webpage","@type":"WebPage","description":"statement by 瑞銀, recorded recently — verbatim quote and source citation.","name":"The cancellation price per Frontage Holdings share is HK$2.37, a 107.2% premium to the 360-day… — 瑞銀 — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1e751-3025-769e-89ce-f5c5c2bcd583","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1e751-3025-769e-89ce-f5c5c2bcd583#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1e751-3025-769e-89ce-f5c5c2bcd583"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1e751-3025-769e-89ce-f5c5c2bcd583#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"The cancellation price per Frontage Holdings share is…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1e751-3025-769e-89ce-f5c5c2bcd583#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-11","isBasedOn":"https://t.me/stockintelligencenews/5715728","text":"方達控股每股註銷價為2.37港元，較過去360日平均股價溢價107.2%，相當於方達控股2025年市盈率約91.6倍。","url":"/claims/01a1e751-3025-769e-89ce-f5c5c2bcd583","spokenByCharacter":{"@type":"Person","name":"瑞銀","@id":"/actors/01a1d49e-d995-7396-8810-d1e55c335b54"}}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.
